Focus: Partner Therapeutics is a mid-cap biotech company focused on biologics development across oncology, neurology, infectious diseases, and respiratory indications. Headquartered in Lexington, MA, the company operates a diversified pipeline spanning early-stage and late-stage programs.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
2 recent layoff filings (12 mo) — 122 affected
Source: state DOL filings via Big Local News
No open roles listed right now. Follow Partner Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Core marketed asset with approaching loss of exclusivity; tablets and oral suspension formulations provide multi-age dosing flexibility.
Help build intelligence for Partner Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Partner Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Generic/ANDA product in mature market; generates stable legacy revenue with minimal growth.
ANDA product offering competitive generic entry in infectious disease; limited differentiation in commoditized market.
2 discontinued, 3 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Confirmed workforce reduction combined with zero active hiring and patent cliff on lead asset elevates near-term restructuring and acquisition risk substantially.